Company profile: Aruna Bio
1.1 - Company Overview
Company description
- Provider of neural exosome-based therapies for central nervous system and neurodegenerative disorders; developer of AB126, a therapeutic neural cell-derived exosome that crosses the blood-brain barrier to reduce neuro-inflammation, promote neuro-protection, and stimulate neuro-regeneration, plus a CNS therapeutic platform and pipeline; also conducts research in stem cells, neural stem cells, and drug toxicity assays.
Products and services
- Neural Exosome Therapeutic Platform: Proprietary platform that develops neural exosome-based therapies for central nervous system and neurodegenerative disorders
- AB126: Neural cell-derived, therapeutic exosome designed to cross the blood-brain barrier, reduce neuro-inflammation, promote neuro-protection, and stimulate neuro-regeneration for treating neurodegenerative diseases
- CNS Therapeutic Pipeline: Multi-indication pipeline of neural exosome therapeutics targeting a broad range of indications, with plans to regularly add new indications
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Aruna Bio
Alector
HQ: United States
Website
- Description: Provider of neuroimmunology- and human genetics-informed antibody therapeutics for neurodegenerative diseases, with a pipeline including AL001 (targets progranulin for frontotemporal dementia with granulin mutation, Phase 3), AL002 (targets TREM2 to enhance microglia for Alzheimer's, Phase 2b), AL101 (increases progranulin for Alzheimer's/Parkinson's, Phase 2), and preclinical ABC candidates ADP027-ABC (GPNMB) and ADP050-ABC (GCase).
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Alector company profile →
LB Pharmaceuticals
HQ: United States
Website
- Description: Provider of development-stage CNS therapeutics focused on LB-102 (n-Methyl amisulpride), a modified amisulpride for schizophrenia, and clinical trials assessing its safety, efficacy, and pharmacokinetics. Also develops improved versions of CNS treatments widely used overseas but not FDA approved for commercialization in the United States.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full LB Pharmaceuticals company profile →
CanniMed
HQ: Canada
Website
- Description: Provider of standardized, pharmaceutical-grade medical cannabis in Canada, operating as a plant biopharmaceutical company under Health Canada’s Access to Cannabis for Medical Purposes Regulations (ACMPR).
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full CanniMed company profile →
Tris Pharma
HQ: United States
Website
- Description: Provider of specialty generic pharmaceuticals leveraging its LiquiXR drug delivery technology for sustained-release formulations, including ADHD treatments with flexible dosing for patients aged 6+, a portfolio of 10 generic products with 20+ in development, technology licensing of its delivery technologies, and partnerships to enhance product development and commercialization.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Tris Pharma company profile →
Pacira BioSciences
HQ: United States
Website
- Description: Provider of specialty pharmaceutical products and pain management technologies, including EXPAREL, a local anesthetic used during surgery to manage pain and reduce opioid use; ZILRETTA, an extended-release injectable for osteoarthritis knee pain; ioveraº, a cryoanalgesia system delivering immediate relief; and pMVL, a multivesicular liposome drug delivery technology.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Pacira BioSciences company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Aruna Bio
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Aruna Bio
2.2 - Growth funds investing in similar companies to Aruna Bio
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Aruna Bio
4.2 - Public trading comparable groups for Aruna Bio
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →